Gilead to buy Immunomedics for $21bn

14-09-2020

Sarah Morgan

Gilead to buy Immunomedics for $21bn

chrisdorney / Shutterstock.com

Gilead Sciences is set to acquire biopharmaceutical company Immunomedics in a $21 billion deal, further strengthening its oncology expertise.


Gilead Sciences, Immunomedics, M&A, mergers and acquisitions, oncology, Trodelvy

LSIPR